Valsartan (Val) is angiotensin II receptor blocker used in the treatment of congestive heart
failure, high blood pressure and post-myocardial infarction [1-4]. Val acts on receptor …

Valsartan is an antihypertensive drug with poor oral bioavailability ranging from 10-35%
because of poor solubility, dissolution and most importantly, extensive first pass hepatic …

The objective of this study was to develop proliposomes and self-nanoemulsifying drug
delivery system (SNEDDS) for a poorly bioavailable drug, valsartan, and to compare their in …

Nanostructured lipid carriers (NLCs), a lipid based colloidal carrier system, offer many
advantages such as increase the solubility, improves the bioavailability and therapeutic …

Valsartan is an antihypertensive drug with poor oral bioavailability ranging from 10-35%
because of poor solubility, dissolution and most importantly, extensive first pass hepatic …

Valsartan is a potent and specific competitive angiotensin II antagonist which is used in the
management of hypertension. It is well absorbed following oral administration, with rather …

The purpose of the present study was to formulate valsartan nanosuspension to increase the
aqueous solubility and to improve its oral bioavailability. Valsartan is a poorly water†…

Antihypertensive treatment reduces the risk of cardiovascular complications in patients with
high mortality with hypertension. Valsartan is highly selective antihypertensive that is rapidly …

Valsartan is an antihypertensive drug used primarily orally, however, due to its hydrophobic
nature it has got low bio-availability thus requiring higher dosage/frequency and causing …

The antihypertensive drug valsartan, has an imperfect bioavailability due to its low solubility,
permeability and excessive first pass hepatic metabolism. So, the goal of this article is to …